William Penley, MD
Medical Oncology · Nashville, TNNPI 1194743914
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,028 and has fallen 97.2% since, to $29 in 2024. That places this record below the midpoint for medical oncology clinicians in TN, where the typical reported total is $6,231.
Across 82 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$275
- AstraZeneca$93
- Tesaro, Inc.$89
- Amgen$78
- Novartis$69
- Sanofi$59
- plus $763 from 29 others
What the payments were for
- Food & beverage$1,41399%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $275 |
| AstraZeneca | 5 | $93 |
| Tesaro, Inc. | 3 | $89 |
| Amgen | 4 | $78 |
| Novartis | 4 | $69 |
| Sanofi | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Taiho Oncology, Inc. | 2 | $49 |
| Incyte Corporation | 3 | $49 |
| Puma Biotechnology, Inc. | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Astellas Pharma US Inc | 3 | $44 |
| Clovis Oncology, Inc. | 2 | $44 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Blueprint Medicines Corporation | 2 | $35 |
| Array Biopharma Inc | 2 | $35 |
| Lilly USA, LLC | 2 | $26 |
| Johnson & Johnson | 2 | $25 |
| Gilead | 2 | $25 |
| Bristol Myers Squibb | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Biocompatibles, Inc. | 1 | $20 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Morphosys, US Inc. | 1 | $17 |
| Mylan Institutional Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Beigene USA, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Exelixis Inc. | 1 | $13 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
| Verastem, Inc. | 1 | $12 |
| Dova Pharmaceuticals | 1 | $12 |
| Bayer | 1 | $11 |
How this compares
$1,425 in reported general payments places this provider in the 30th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Nashville
- William PaoNashville$838K
- Dana ThompsonNashville$339K
- Robert RamirezNashville$321K
- Mace RothenbergNashville$318K
- Melissa JohnsonNashville$290K
- Cathy EngNashville$231K
- David SpigelNashville$167K
- Michael GibsonNashville$141K
- Jordan BerlinNashville$120K
- Vandana AbramsonNashville$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.